Thanks @Akki in bring the AAV issues back on the spotlight. In my Post #: 47917780 of 07/10/2020, I have commented on AAV's serious issues as follows:
CPP doesn't have the many issues that AAV (Adeno Associated Virus) has such as cargo size limitation, immunogenicity, adverse side effects due to immunal reaction, complex to scale up in commercial production, etc.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/ Immunogenicity could be a show stopper as the body could develop life long imunity. If the 1st dose was not enough, subsequent doses would have diminishing effect. Worst is the same patient could be immune to all other AAV based drugs for life.
Lipid Nanoparticles Delivery (LNP) is the other viable transport method and on 14.03.2019 PYC has entered into collaboration with Professor Dan Peerof Tel Aviv University in Israel. Professor Peer is considered a honcho in the field of LNP systems. https://ramot.org/news/2019/collaboration-agreement-with-phylogica-sirna-delivery
PYC is definitely in the right space at the right time!
PYC Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)